The European Union Has Announced the Finalized EU GMP Annex 1
The European Union has announced the finalized EU GMP Annex 1 for manufacturing sterile medicinal products. It is creating some reservations for manufacturers who are not certain how these changes may impact their total manufacturing operation and output. In particular, as the August 2023 deadline approaches manufacturers will need to take time to unpack the changes…
This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.
Promoted content from Benchmark Products on MarketScale.
Free workspace
Turn your Healthcare expertise into content.
Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.
The European Union has announced the finalized EU GMP Annex 1 for manufacturing sterile medicinal products. It is creating some reservations for manufacturers who are not certain how these changes may impact their total manufacturing operation and output. In particular, as the August 2023 deadline approaches manufacturers will need to take time to unpack the changes and understand how they will impact their standard operating procedures.
Jennifer Parker, Director of Marketing at Benchmark Products, is advising manufacturers not to wait to consider these new policies. She anticipates the evaluation of SOPs against the guidelines in Annex 1 will require manufacturers to revise and overhaul processes, as well as implement entirely new processes.
Jennifer’s Thoughts:
Although drafts of the new Annex 1 regulations that govern the manufacturers of sterile medicinal products have been circulating for some years now, it still presents a number of challenges when it was actually released in August of this year. Companies will have some barriers when it comes to clients which they will need to meet by the deadline of August next year.
The first one is understanding the complexity of the Annex 1 regulations, being a 50-page document and affecting almost all the areas of production, it will take some time to read, understand, and then evaluate against your own SOPs. And then that’s where I think the biggest challenge is, around evaluating those SOPs against the guidelines. Will you need to rewrite entire operating procedures? Do you need to add new ones where there weren’t any before? And then finally, how are you going to validate your new SOPs? What criteria will you use and the types of products and procedures that you have in place already, will they be sufficient enough to meet the validation criteria?
These are all complex decisions that companies need to make within the deadline. So I really urge manufacturers that are undergoing this process to start early, form a team, and really understand how much work will be involved to get more manufacturing facilities up to compliance.
Part of this channel
Benchmark Products
ISO-certified cleanroom supplies for life science manufacturers.
Your experts belong here
Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.
Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.
